文档介绍：晚期结肠癌行西妥昔单抗联合FOLFIRI化疗的临床分析
[摘要] 目的 研究在晚期結肠癌患者的治疗过程中运用西妥昔单抗联合FOLon， 13 cases of stabilization， and 2 cases of progress. The total effective rate of treatment was %. In the total effective rate of treatment， patients in group B were higher than patients in group A， and the difference in group B was statistically significant （χ2=，P<）. There was no significant difference in the quality of life between the two groups before treatment（P>）. After treatment， the quality of life of group B was significantly improved， and the difference was statistically significant （P<）. In the occurrence of toxic side effects， group A patients had thrombocytopenia in 12 cases， leukopenia in 14 cases， liver function impairment in 15 cases， and nausea and vomiting in 32 cases. Group B patients had thrombocytopenia in 11 cases， leukopenia in 14 cases， and liver function impairment of 13 cases， 33 cases of nausea and vomiting. In the incidence of toxic side effects， the two groups of patients had no significant difference（P>）. Conclusion The application of cetuximab combined with FOLFIRI chemotherapy in the treatment of advanced colon cancer can effectively improve the clinical symptoms of patients， and has important clinical application value. [Key words] Advanced colon cancer； Cetuximab； FOLFIRI chemotherapy； Clinical analysis
目前在临床上一种比较常见的恶性肿瘤疾病之一就是结肠癌[1]，在发病的早期症状不太明显，临床上收治的部分结肠癌患者已经处于晚期，治疗方式主要对患者进行化疗，又可把常规的化疗治疗或与单克隆抗体靶向药物治疗相结合[2]。该文在研究中方便选取了该院在2015年9月—2018年9月收治的88例晚期结肠癌患者，对其运用西妥昔单抗联合FOLFIRI化疗治疗，分析在这一过程中取得的临床治疗效果，主要包括以下内容。
1 资料与方法
一般资料
该文为了研究，方便选取了该院收治的88例晚期结肠癌患者。全部患者均符合行业协会对晚期结肠癌制定的诊断标准。将88例晚期结肠癌患者随机分为A组和B组，每组内都包含44例患者，在A组中男20例，女24例，年龄30～81岁，，在B组中男33例，女11例，年龄28～80岁，。在性别、年龄与病程等一般资料上A组和B组患者，差异无统计学意义（P>），具有可比性。该次研究得到了患者及患者家属的同意与授权，研究所选病例得到了伦理委员会的批准。
研究方法
对A组患者采用的是FOLFIRI化疗方式进行治疗，对患者运用伊立替康进行90 min的静滴，第1天开始用药，并运用200 mg/m2的亚叶酸钙（国药准字H20054300），进行2 h的静滴，同样是第1天用药，之后对